drugset / Trial / NCT02121613
PERmixon® in LUTS Evaluation Study (PERLES)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to support the efficacy of Permixon 160 mg b.i.d. in treating subjects with symptomatic Benign Prostatic Hyperplasia (BPH), compared to placebo, using Tamsulosine LP 0.4 mg as a reference treatment.
Timeline
- Start
- 2014-04
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Permixon | Unknown | 160 mg | Oral |
| Subject | Tamsulosin | Other / unclassified | 0.4 mg | Oral |